公共卫生——邓瑶

　　一、个人简介

　　邓瑶，女，汉族，1970年10月出生，硕士，研究员。1994年毕业于复旦大学公共卫生学院预防医学专业，获医学学士学位，2005年获中国医学科学院微生物与免疫学硕士学位。

　　主要从事冠状病毒及正痘病毒的病原学、诊断学、免疫学、疫苗学研究。先后研发HIV 、HCV、HBV、 Influenza Virus、Zika MERS-CoV、SARS-CoV-2 、MPOX的蛋白疫苗、核酸疫苗及病毒载体疫苗，在小动物和恒河猴体内评价疫苗免疫应答效果，建立了多种基于假病毒中和抗体检测平台。主持和参与了国家自然科学基金面上项目、科技部重点专项、重点研发计划等多项课题。在SCI收录杂志上发表第一作者及通讯作者科研论文20余篇，包括Signal Transduct Target Ther，Emerg Microbes Infect，Cellular & Molecular Immunology, Ebiomedicine。其中MERS-CoV的相关工作获得2022年中华医学会医学科学技术奖三等奖，申请专利1项。

　　二、主要研究方向

　　致力于医学病毒学研究与病毒病应急防控，包括新型冠状病毒（SARS-CoV，MERS-CoV，SARS-CoV-2等）与痘病毒（天花/猴痘/痘苗）病原生物学与疫苗研发及效果评价。重要病毒病（新发病毒病与肝炎）的免疫学及新型疫苗研究。

　　三、代表性论文、成果

　　1.Deng Y, Yu Li, Ren Yang, Wenjie Tan, SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients, Cellular & Molecular Immunology, 2021, 18: 2040-2041

　　2.Qiaohong Chu,Baoying Huang,Mengzhe Li,Xueting Cheng,Shuting Huo,Jiao Ren,Yao Deng &Wenjie Tan Non-replicating vaccinia virus NTV as an effective next-generation smallpox and monkeypox vaccine: evidence from mouse and rhesus monkey models. Emerg Microbes Infect.2023 Dec;12(2):2278900 (SCI: 13.2)

　　3.Yuting Liu, Yao Deng, Sheng Niu, Na Zhu, Jingdong Song, Xiaoshuang Zhang, Weiting Su, Wenhui Nie, Roujian Lu, David M Irwin, George Fu Gao, Wenling Wan, Qihui Wang, Wenjie Tan, Shuyi Zhang.Discovery and identification of a novel canine coronavirus causing a diarrhea outbreak in Vulpes. Science Bulletin2023 Nov 15;68(21):2598-2606. doi: 10.1016/j.scib.2023.09.011. Epub 2023 Sep 12. (SCI: 18.9)

　　4.Jinni Chen,Yao Deng,Baoying Huang,Di Han,Wen Wang,Mengjing Huang, Chengcheng Zhai,Zhimin Zhao,Ren Yang,Ying Zhao,Wenling Wang,Desheng Zhai,Wenjie Tan. DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice. Front Immunol. 2022 Feb 24:13:827605. (SCI: 8.786)

　　5.Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, Wang W, Liu J, Lu S, Zhan Z, Wang Y, A R, Wang W, Niu P, Zhao L, Li S, Ma X, Zhang L, Zhang Y, Yao W, Liang X, Zhao J, Liu Z, Peng X, Li H, Tan W. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6(1):213.

　　6.Yang R#, Lan J#, Huang B#, A R, Lu M, Wang W, Wang W, Li W, Deng Y*, Wong G*, Tan W*, Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections, EBIOMEDICINE, 2020;58:102890.

　　7.Ren Yang, Baoying Huang, Ruhan A, Wenhui Li, Wenling Wang , Yao Deng*, Wenjie Tan. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf Health.2020 Dec;2(4):226-231.

　　8.Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018 Apr 4;7(1):60.

　　9.Deng Y, Chuai X, Chen P, Chen H, Wang W, Ruan L1, Li W, Tan W。Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccineinduced more robust and lasting immunity in rhesus macaques. Vaccine. 2017 Jun 5;35(25):3347-3353.

　　10.Deng Y, Guan J, Wen B, Zhu N, Chen H, Song J, Yang Y, Wang Y, Tan W. Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles.PLoS One. 2013 Apr 23;8(4):e62684.